In a randomized controlled clinical trial, Gawrieh et al103 found that saroglitazar (4 mg) significantly improved alanine aminotransferase levels and atherosclerotic dyslipidemia in patients with NAFLD/NASH. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.